We are live on ! Find out more
HRTX icon

Heron Therapeutics
HRTX

151 hedge funds and large institutions have $192M invested in Heron Therapeutics in 2023 Q4 according to their latest regulatory filings, with 30 funds opening new positions, 45 increasing their positions, 38 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

1,289% more call options, than puts

Call options by funds: $2.19M | Put options by funds: $158K

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

57% more capital invested

Capital invested by funds: $122M → $192M (+$70M)

18% more repeat investments, than reductions

Existing positions increased: 45 | Existing positions reduced: 38

7% more funds holding

Funds holding: 141 → 151 (+10)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

8.86% less ownership

Funds ownership: 84.11% → 75.24% (-8.9%)

Holders
151
Holders Change
+10
Holders Change %
+7.09%
% of All Funds
2.2%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
30
Increased
45
Reduced
38
Closed
18
Calls
$2.19M
Puts
$158K
Net Calls
+$2.04M
Net Calls Change
+$669K

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$5.64M
2
TC
Tejara Capital
United Kingdom
+$3.49M
3
Renaissance Technologies
Renaissance Technologies
New York
+$1.75M
4
MAM
Monaco Asset Management
Monaco
+$1.68M
5
CPC
Congress Park Capital
New York
+$1.33M

Top Sellers

Rank Fund Capital Flow
1
BBA
Baker Bros. Advisors
New York
-$8.38M
2
JP Morgan Chase
JP Morgan Chase
New York
-$7.42M
3
GPP
Great Point Partners
Connecticut
-$4.88M
4
DTC
Deep Track Capital
Connecticut
-$2.15M
5
BlackRock
BlackRock
New York
-$1.06M
Name Holding Trade Value Shares
Change 		Change in
Stake
Los Angeles Capital Management
26
Los Angeles Capital Management
California
$874K +$189K +171,250 +50%
NAM
27
Nexpoint Asset Management
Texas
$809K -$25.7K -23,381 -5%
Bank of New York Mellon
28
Bank of New York Mellon
New York
$687K +$56.1K +50,975 +14%
Citadel Advisors
29
Citadel Advisors
Florida
$649K +$409K +371,389 +3,574%
GCP
30
GSA Capital Partners
United Kingdom
$577K +$374K +339,448 New
Commonwealth Equity Services
31
Commonwealth Equity Services
Massachusetts
$558K +$15K +13,578 +4%
CM
32
CM Management
Florida
$553K -$138K -125,000 -28%
ZDA
33
Zweig-DiMenna Associates
New York
$544K – – –
Fidelity Investments
34
Fidelity Investments
Massachusetts
$543K +$43.1K +39,144 +14%
ZIM
35
Zacks Investment Management
Illinois
$529K +$343K +311,429 New
RB
36
Richmond Brothers
Michigan
$504K +$213K +193,697 +188%
KBC Group
37
KBC Group
Belgium
$492K – – –
HF
38
HRT Financial
New York
$339K +$220K +199,908 New
AllianceBernstein
39
AllianceBernstein
Tennessee
$329K – – –
Bank of America
40
Bank of America
North Carolina
$317K +$104K +94,694 +103%
Barclays
41
Barclays
United Kingdom
$304K +$137K +124,044 +227%
Jane Street
42
Jane Street
New York
$283K +$142K +128,914 +342%
PAM
43
Panagora Asset Management
Massachusetts
$236K +$153K +139,113 New
RhumbLine Advisers
44
RhumbLine Advisers
Massachusetts
$231K +$655 +595 +0.4%
Acadian Asset Management
45
Acadian Asset Management
Massachusetts
$229K +$149K +134,877 New
UBS Group
46
UBS Group
Switzerland
$207K +$64.3K +58,410 +93%
XT
47
XTX Topco
Cayman Islands
$177K +$115K +104,274 New
PBM
48
Propel Bio Management
California
$177K +$115K +104,195 New
N
49
Nuveen
North Carolina
$156K – – –
WMSA
50
Weiss Multi-Strategy Advisers
New York
$153K -$42.5K -38,559 -30%
1
2
3 4 5

HRTX Hedge Fund Activity: Q4 2023 in Review

151 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Heron Therapeutics (HRTX) for Q4 2023, worth a combined $192M — up 57% from $122M a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new HRTX positions and 18 closed out — a net gain of 12 holders — while 45 added to existing stakes and 38 trimmed.

The largest buyer was OrbiMed, adding an estimated $5.64M. The largest seller was Baker Bros. Advisors, exiting entirely with an estimated $8.38M sold.

  • 151 institutional investors held Heron Therapeutics (HRTX) as of Q4 2023, up from 141 in Q3 2023.
  • Funds reported $192M of Heron Therapeutics stock for Q4 2023, up 57% quarter-over-quarter.
  • 30 funds opened new Heron Therapeutics positions in Q4 2023 and 18 closed out, a net change of +12 holders.
  • The largest Heron Therapeutics buyer in Q4 2023 was OrbiMed, an estimated $5.64M added.
  • The largest Heron Therapeutics seller in Q4 2023 was Baker Bros. Advisors, an estimated $8.38M sold.

Based on aggregated 13F filings for Q4 2023.